Skip to main content

Table 1 Characteristics of the included studies

From: Prognostic and clinicopathological value of Beclin-1 expression in hepatocellular carcinoma: a meta-analysis

References Year Country No. of patients Gender (M/F, n) Age range (years) Method Antibody dilution Counting method Cut-off staining Reduced Beclin-1 expression (%) OS data provided
Ding [15] 2008 China 300 252/48 NR IHC 1:50 IRS* 10% 205/300 (68.33) Yes
Kang [21] 2013 China 50 47/3 28–71 IHC NR IRS 4 11/50 (22.00) No
Lee [22] 2013 Korea 190 158/32 29–76 IHC NR IRS 6 179/190 (94.21) Yes
Guo [26] 2013 China 54 39/15 33–75 IHC 1:150 IRS 3 10/54 (18.52) No
Qiu [14] 2014 China 103 85/18 21–79 IHC 1:100 IRS 8 81/103 (78.64) Yes
Wu [16] 2014 China 156 143/13 NR IHC 1:100 IRS 6 83/156 (53.21) Yes
Osman [23] 2015 Egypt 65 51/14 40–74 IHC 1:100 IRS* 10% 32/65 (49.23) No
Yang [27] 2015 China 50 39/11 26–74 IHC NR IRS 3 11/50 (22.00) No
Al-Shenawy [24] 2016 Egypt 35 20/15 23–75 IHC 1:350 IRS 1 18/35 (51.43) No
Zhou [25] 2016 China 83 69/14 NR IHC 1:100 NR NR 45/83 (54.22) Yes
  1. M male, F female, NR not reported, IHC immunohistochemistry, IRS immunoreactive score, IHC expression was evaluated integrating proportion and intensity of positive staining, IRS* IHC expression was evaluated by percent positivity, OS overall survival